• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Agios wins FDA nod for targeted AML drug Tibsovo fiercepharma
    July 24, 2018
    A year after its Celgene-partnered drug Idhifa won FDA approval to treat certain patients with relapsed/refractory acute myeloid leukemia, Agios Pharmaceuticals has scored its first FDA nod for a wholly-owned medicine, Tibsovo.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service